18 research outputs found
Intravenous Formulation of HET0016 Decreased Human Glioblastoma Growth and Implicated Survival Benefit in Rat Xenograft Models
Glioblastoma (GBM) is a hypervascular primary brain tumor with poor prognosis. HET0016 is a selective CYP450 inhibitor, which has been shown to inhibit angiogenesis and tumor growth. Therefore, to explore novel treatments, we have generated an improved intravenous (IV) formulation of HET0016 with HPßCD and tested in animal models of human and syngeneic GBM. Administration of a single IV dose resulted in 7-fold higher levels of HET0016 in plasma and 3.6-fold higher levels in tumor at 60 min than that in IP route. IV treatment with HPßCD-HET0016 decreased tumor growth, and altered vascular kinetics in early and late treatment groups (p \u3c 0.05). Similar growth inhibition was observed in syngeneic GL261 GBM (p \u3c 0.05). Survival studies using patient derived xenografts of GBM811, showed prolonged survival to 26 weeks in animals treated with focal radiation, in combination with HET0016 and TMZ (p \u3c 0.05). We observed reduced expression of markers of cell proliferation (Ki-67), decreased neovascularization (laminin and αSMA), in addition to inflammation and angiogenesis markers in the treatment group (p \u3c 0.05). Our results indicate that HPßCD-HET0016 is effective in inhibiting tumor growth through decreasing proliferation, and neovascularization. Furthermore, HPßCD-HET0016 significantly prolonged survival in PDX GBM811 model
Chimeric Mouse model to track the migration of bone marrow derived cells in glioblastoma following anti-angiogenic treatments
Bone marrow derived cells (BMDCs) have been shown to contribute in the tumor development. In vivo animal models to investigate the role of BMDCs in tumor development are poorly explored. We established a novel chimeric mouse model using as low as 5 × 10(6) GFP+ BM cells in athymic nude mice, which resulted in \u3e70% engraftment within 14 d. In addition, chimera was established in NOD-SCID mice, which displayed \u3e70% with in 28 d. Since anti-angiogenic therapies (AAT) were used as an adjuvant against VEGF-VEGFR pathway to normalize blood vessels in glioblastoma (GBM), which resulted into marked hypoxia and recruited BMDCs to the tumor microenvironment (TME). We exploited chimeric mice in athymic nude background to develop orthotopic U251 tumor and tested receptor tyrosine kinase inhibitors and CXCR4 antagonist against GBM. We were able to track GFP+ BMDCs in the tumor brain using highly sensitive multispectral optical imaging instrument. Increased tumor growth associated with the infiltration of GFP+ BMDCs acquiring suppressive myeloid and endothelial phenotypes was seen in TME following treatments. Immunofluorescence study showed GFP+ cells accumulated at the site of VEGF, SDF1 and PDGF expression, and at the periphery of the tumors following treatments. In conclusion, we developed a preclinical chimeric model of GBM and phenotypes of tumor infiltrated BMDCs were investigated in context of AATs. Chimeric mouse model could be used to study detailed cellular and molecular mechanisms of interaction of BMDCs and TME in cancer
Changes in the tumor microenvironment and outcome for TME-targeting therapy in glioblastoma: A pilot study.
Glioblastoma (GBM) is a hypervascular and aggressive primary malignant tumor of the central nervous system. Recent investigations showed that traditional therapies along with antiangiogenic therapies failed due to the development of post-therapy resistance and recurrence. Previous investigations showed that there were changes in the cellular and metabolic compositions in the tumor microenvironment (TME). It can be said that tumor cell-directed therapies are ineffective and rethinking is needed how to treat GBM. It is hypothesized that the composition of TME-associated cells will be different based on the therapy and therapeutic agents, and TME-targeting therapy will be better to decrease recurrence and improve survival. Therefore, the purpose of this study is to determine the changes in the TME in respect of T-cell population, M1 and M2 macrophage polarization status, and MDSC population following different treatments in a syngeneic model of GBM. In addition to these parameters, tumor growth and survival were also studied following different treatments. The results showed that changes in the TME-associated cells were dependent on the therapeutic agents, and the TME-targeting therapy improved the survival of the GBM bearing animals. The current GBM therapies should be revisited to add agents to prevent the accumulation of bone marrow-derived cells in the TME or to prevent the effect of immune-suppressive myeloid cells in causing alternative neovascularization, the revival of glioma stem cells, and recurrence. Instead of concurrent therapy, a sequential strategy would be better to target TME-associated cells
Vascular mimicry in glioblastoma following anti-angiogenic and anti-20-HETE therapies
Glioblastoma (GBM) is one hypervascular
and hypoxic tumor known among solid tumors.
Antiangiogenic therapeutics (AATs) have been tested as
an adjuvant to normalize blood vessels and control
abnormal vasculature. Evidence of relapse exemplified
in the progressive tumor growth following AAT reflects
development of resistance to AATs. Here, we identified
that GBM following AAT (Vatalanib) acquired an
alternate mechanism to support tumor growth, called
vascular mimicry (VM). We observed that Vatalanib
induced VM vessels are positive for periodic acid-Schiff
(PAS) matrix but devoid of any endothelium on the inner
side and lined by tumor cells on the outer-side. The
PAS+ matrix is positive for basal laminae (laminin)
indicating vascular structures. Vatalanib treated GBM
displayed various stages of VM such as initiation
(mosaic), sustenance, and full-blown VM. Mature VM
structures contain red blood cells (RBC) and bear
semblance to the functional blood vessel-like structures,
which provide all growth factors to favor tumor growth.
Vatalanib treatment significantly increased VM
especially in the core of the tumor, where HIF-1α was
highly expressed in tumor cells. VM vessels correlate
with hypoxia and are characterized by co-localized
MHC-1+ tumor and HIF-1α expression. Interestingly,
20-HETE synthesis inhibitor HET0016 significantly
decreased GBM tumors through decreasing VM
structures both at the core and at periphery of the
tumors. In summary, AAT induced resistance characterized by VM is an alternative mechanism adopted by
tumors to make functional vessels by transdifferentiation
of tumor cells into endothelial-like cells to supply
nutrients in the event of hypoxia. AAT induced VM is a
potential therapeutic target of the novel formulation of
HET0016. Our present study suggests that HET0016 has
a potential to target therapeutic resistance and can be
combined with other antitumor agents in preclinical and
clinical trials
CXCR2-Expressing Tumor Cells Drive Vascular Mimicry in Antiangiogenic Therapy–Resistant Glioblastoma
BACKGROUND: Glioblastoma (GBM) was shown to relapse faster and displayed therapeutic resistance to antiangiogenic therapies (AATs) through an alternative tumor cell-driven mechanism of neovascularization called vascular mimicry (VM). We identified highly upregulated interleukin 8 (IL-8)-CXCR2 axis in tumor cells in high-grade human glioma and AAT-treated orthotopic GBM tumors. METHODS: Human GBM tissue sections and tissue array were used to ascertain the clinical relevance of CXCR2-positive tumor cells in the formation of VM. We utilized U251 and U87 human tumor cells to understand VM in an orthotopic GBM model and AAT-mediated enhancement in VM was modeled using vatalanib (anti-VEGFR2) and avastin (anti-VEGF). Later, VM was inhibited by SB225002 (CXCR2 inhibitor) in a preclinical study. RESULTS: Overexpression of IL8 and CXCR2 in human datasets and histological analysis was identified as a bonafide candidate to validate VM through in vitro and animal model studies. AAT-treated tumors displayed a higher number of CXCR2-positive GBM-stem cells with endothelial-like phenotypes. Stable knockdown of CXCR2 expression in tumor cells led to decreased tumor growth as well as incomplete VM structures in the animal models. Similar data were obtained following SB225002 treatment. CONCLUSIONS: The present study suggests that tumor cell autonomous IL-8-CXCR2 pathway is instrumental in AAT-mediated resistance and VM formation in GBM. Therefore, CXCR2 can be targeted through SB225002 and can be combined with standard therapies to improve the therapeutic outcomes in clinical trials
17JBN-3091.pdf
Exosomes, a component of extracellular vesicles, are shown to carry important small RNAs, mRNAs, protein, and bioactive
lipid from parent cells and are found in most biological fluids. Investigators have demonstrated the importance of
mesenchymal stem cells derived exosomes in repairing stroke lesions. However, exosomes from endothelial progenitor
cells have not been tested in any stroke model, nor has there been an evaluation of whether these exosomes target/home
to areas of pathology. Targeted delivery of intravenous administered exosomes has been a great challenge, and a targeted
delivery system is lacking to deliver naïve (unmodified) exosomes from endothelial progenitor cells to the site of interest.
Pulsed focused ultrasound is being used for therapeutic and experimental purposes. There has not been any report
showing the use of low-intensity pulsed focused ultrasound to deliver exosomes to the site of interest in stroke models.
In this proof of principle study, we have shown different parameters of pulsed focused ultrasound to deliver exosomes
in the intact and stroke brain with or without intravenous administration of nanobubbles. The study results showed that
administration of nanobubbles is detrimental to the brain structures (micro bleeding and white matter destruction) at peak
negative pressure of >0.25 megapascal , despite enhanced delivery of intravenous administered exosomes. However,
without nanobubbles, pulsed focused ultrasound enhances the delivery of exosomes in the stroke area without altering
the brain structures.</p
HET0016 decreases lung metastasis from breast cancer in immune-competent mouse model - Fig 3
<p><b>Protein expression analyses in lung metastasis (A) and primary tumor (D)</b>. (A) Photomicrographs of Western blotting for pAKT, total AKT, pNFκB (p65 subunit), total NFκB (p65 subunit), MMP-2, MMP-9, CD24, CD44, E-cadherin, N-cadherin and β-actin in lungs tissues of vehicle and HPßCD-HET0016 treated group; (B) Semi-quantitative analysis (densitometry) of Western blotting for pAKT, total AKT, pNFκB (p65 subunit), total NFκB (p65 subunit) and (C) for MMP-2, MMP-9, CD24, CD44, E-cadherin, N-cadherin in lungs tissues of vehicle and HPßCD-HET0016 groups; (D) Representative pictures of immunostaining of primary tumor in vehicle and HPßCD-HET0016 treatment groups. (E) Semi-quantitative analysis of immunostaining for MMP-2, MMP-9 protein levels in primary tumor; Significant values from ANOVA followed by Bonferroni’s test are represented by mean ± SEM *p < 0.05 or ***p < 0.0001 in comparison to untreated group (vehicle). Images were taken 40x magnification. Arrows show the positive labelling.</p